Cargando…
EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers
Clear cell carcinoma and endometrioid adenocarcinoma are histologic subtypes of ovarian and uterine cancer that demonstrate unique clinical behavior but share common underlying genomic aberrations and oncogenic pathways. ARID1A mutations are more frequently identified in these tumors, in comparison...
Autores principales: | Alldredge, Jill K., Eskander, Ramez N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663065/ https://www.ncbi.nlm.nih.gov/pubmed/29093822 http://dx.doi.org/10.1186/s40661-017-0052-y |
Ejemplares similares
-
Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma
por: Yoneoka, Yutaka, et al.
Publicado: (2018) -
Role of serum microRNAs as biomarkers for endometriosis, endometrioid carcinoma of ovary & endometrioid endometrial cancer
por: Kumari, Priti, et al.
Publicado: (2022) -
The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas
por: Zhan, Xiangbo, et al.
Publicado: (2019) -
Genomic mutation features identify distinct BRCA-associated mutation characteristics in endometrioid carcinoma and endometrioid ovarian carcinoma
por: Cao, Canhui, et al.
Publicado: (2021) -
Hypoxia and Angiogenesis in Endometrioid Endometrial Carcinogenesis
por: Horrée, Nicole, et al.
Publicado: (2007)